CompletedNot Applicable

Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole

50 participantsStarted 2012-06

Plain-language summary

Study design to define improved management of patients with hepatic alveolar echinococcosis treated with albendazole and especially make appropriate and timely decision of treatment withdrawal . Based on exploratory analysis of existing and newly developed biological and imaging exams, for diagnosis and follow-up, and study of the relationship of these markers to the viability of the parasite and/or the activity of the parasitic lesions The study included two series of patients: operated on (curative hepatectomy) // non-operated on

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * hepatic alveolar echinococcosis * without antiparasitic treatment or with antiparasitic treatment and hepatectomy programmed Exclusion Criteria: * Patients with exclusively extra-hepatic form of alveolar echinococcosis * Women without effective contraception (Contraindication to benzimidazoles) * The immunosuppressed patients or receiving an immunosuppressive treatment will not be the object of a stop of the post-operative treatment by albendazole on 1 year after the intervention of radical resection; they can be included in the study but will receive the albendazole during 2 years; this exclusion applies to the patients treated by liver transplant.

What they're measuring

Ratio of non-operated on patients with negative viability markers after a 4 years benzimidazole treatment

Timeframe: 4 years after last inclusion

Trial details

NCT IDNCT02876146

SponsorCentre Hospitalier Universitaire de Besancon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08

View on ClinicalTrials.gov More Alveolar Echinococcosis trials